Rheinmetall's Cash Conversion Target Is Gone — Now the Market Wants Proof

Rheinmetall's chief executive has been buying his own stock. The analysts have been cutting their price targets. Between those two signals sits a €78 billion order book and a cash flow statement that has yet to catch up with it.

Armin Theodor Papperger picked up Rheinmetall shares worth €200,295.60 on Wednesday, according to a mandatory disclosure, following an earlier Xetra purchase worth an aggregate €502,484.40 reported on Thursday. The buys are a personal vote of confidence at a moment when outside assessments have turned more guarded. Bernstein Research downgraded the stock from "Outperform" to "Market-Perform" on Wednesday, according to dpa-AFX, and trimmed its price target to €1,000 from €1,200. JPMorgan, also on Wednesday, cut its target to €1,150 from €1,350 while keeping a "Neutral" rating; analyst David Perry pointed to repeated profit warnings and growing uncertainty over long-term revenue prospects for several land-systems products.

The numbers behind that caution are stark in one respect and reassuring in another. At the end of September, the backlog stood at €78 billion, with 70% of it made up of firm orders. Cumulative operating free cash flow for the nine-month period, however, came in at roughly minus €1.7 billion — precisely ?€1,698 million. Rheinmetall therefore has an enormous pipeline of future business and a substantial bill to pre-finance before that business turns into money.

A cash target quietly shelved

The company still expects a positive operating free cash flow for 2026, but capital expenditure is likely to exceed €1 billion, meaning the remainder of the year has to deliver a hefty inflow to get there. The third quarter alone produced minus €82 million in operating free cash flow, partly offset by an advance payment of around €150 million received in October. That single payment illustrates how much the timing of customer money matters. Rheinmetall has abandoned its previous target of cash conversion above 40% — a concession that shifts the emphasis from stated ambitions to the cash actually collected.

Should investors sell immediately? Or is it worth buying Rheinmetall?

What went wrong is now fairly specific. In this week's guidance revision, the company flagged likely delays to the Bundeswehr's Arminius project and to acceptance procedures for artillery ammunition. The awarding of the Boxer programme, along with related advance payments and revenue contributions, is expected to slip into the following year. German price reviews on the Arminius contract are a particular bottleneck; according to media reports, approval is not expected before February 2027. Without that contract, Rheinmetall is likely to fall short of its targeted order intake by year-end.

The revised outlook now pencils in roughly €13.2 billion of revenue for 2026 at an operating margin of 18.5% — high expansion spending meeting lower expected proceeds than previously planned. Reuters reported on Thursday that this was the second guidance cut within three months.

Growth is not the problem

None of this reflects weak demand. Revenue for the first nine months of 2026 climbed 38% to €8,376 million, and operating profit reached €1,339 million, a margin of 16%. Artillery ammunition deliveries for Ukraine and demand for air-defence systems were among the drivers. New business keeps arriving too: on 29 October, OCCAR commissioned the Artec joint venture with additional Schakal wheeled armoured vehicles, with Rheinmetall's share of the order value in the mid-three-digit million-euro range.

The bull case rests on those delays proving temporary. If Arminius is awarded next year and ammunition acceptances gather pace, deferred revenue and advance payments could swing back and support the trajectory — making the current strain a question of timing rather than of substance. The bear case starts where individual slippages harden into a pattern, stretching the period during which Rheinmetall must fund capacity and production while the backlog ties up capital. Delays at Boxer's Arminius programme and in artillery ammunition acceptance testing are now expected to run into 2027.

What Hamburg has to deliver

The next fixed date for resolving this debate is the capital markets day, announced for 25–27 November in Hamburg. Concrete statements on the Arminius award, ammunition acceptances and the path of cash flow would sharpen both scenarios considerably; credible progress on the very items that deferred revenue and down payments would carry the most weight. Further out, a decision on the XM30 programme is expected in 2027.

For investors, the choice comes down to getting ahead of events or waiting for confirmation. Backing a catch-up requires a defensible assumption about order execution. Demanding operating evidence first means watching for more reliable acceptances and an improvement in cash generation. Those are the yardsticks against which Rheinmetall's recovery story will be measured.

Ad

Rheinmetall Stock: New Analysis - 7 November

Fresh Rheinmetall information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Rheinmetall analysis...